Is your mAb optimized for
SubQ yet?
Cutting edge, viscosity-reduction technology for
monoclonal antibodies
This patented platform technology uses GRAS excipients to enable innovator mAbs and biosimilars for SubQ delivery, optimized dosing and enhanced market acceptance.
HILOPRO Technology
TM
Upgrade your mAb from IV to SubQ.
Re-imagine your biologic API delivered subcutaneously in a single dose up to 375mg in a 1.5mL syringe.
Proof of concept for your mAb in
8 Weeks !
